Frontiers in Oncology | |
Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens | |
Oncology | |
Keiju Sasaki1  Kota Ouchi1  Sakura Taniguchi1  Keigo Komine1  Hiroo Imai1  Hidekazu Shirota1  Yoshifumi Kawamura1  Yuki Kasahara1  Chikashi Ishioka1  Masanobu Takahashi1  Yuya Yoshida1  Ken Saijo1  | |
[1] Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan;Department of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, Japan; | |
关键词: immune check point inhibitor; pembrolizumab; head and neck cancer; depth of response; predictive factor; | |
DOI : 10.3389/fonc.2023.1230731 | |
received in 2023-05-29, accepted in 2023-07-24, 发布年份 2023 | |
来源: Frontiers | |
【 摘 要 】
BackgroundPembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of patients with R/M HNSCC treated with pembrolizumab-containing regimens remains unclear.MethodsThis study included 66 patients with R/M HNSCC who received a pemblolizumab-containing regimen as a first-line therapy at Tohoku University Hospital, Sendai, Japan. The patients’ characteristics, combined positive score, baseline tumor size, tumor response, DpR, overall survival (OS), progression-free survival (PFS), PFS2, and adverse events were reviewed. The associations between DpR and survival outcomes were analyzed.ResultsThe 1 year-OS and 1 year-PFS rates of pembrolizumab-containing regimens were 69.4% and 24.4%, respectively. The response rate was 28.8%. The mean and median values of tumor change from baseline were 5.1% and −9.0%. In the correlation analysis, a significant negative correlation was observed between tumor change rate from baseline and survival outcomes (OS: r= −0.41, p=0.0017; PFS: r=−0.49, p<0.001). In the multivariate analysis, DpR with tumor change of ≤−45 was associated with better OS and PFS.ConclusionDpR induced by pembrolizumab-containing regimens may be a predictive factor for OS and PFS in patients with R/M HNSCC.
【 授权许可】
Unknown
Copyright © 2023 Saijo, Imai, Ouchi, Sasaki, Yoshida, Kawamura, Taniguchi, Kasahara, Komine, Shirota, Takahashi and Ishioka
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202310102046505ZK.pdf | 2000KB | download |